DOSAGE AND ADMINISTRATION OF ANTI-IGF-1R, ANTI-ErbB3 BISPECIFIC ANTIBODIES, USES THEREOF AND METHODS OF TREATMENT THEREWITH

1 - 167 . (canceled)

168 . A method of treating a patient with pancreatic cancer comprising administering to the patient a therapeutically effective amount of

(a) a bispecific binding molecule comprising:

i) an IGF-1R binding site comprising heavy and light chain variable regions, wherein the heavy chain variable region comprises a CDR1 comprising amino acid numbers 26-35 of SEQ ID NO: 3, a CDR2 comprising amino acid numbers 51-66 of SEQ ID NO: 3, a CDR3 comprising amino acid numbers 99-111 of SEQ ID NO: 3, and the light chain variable region comprises a CDR1 comprising amino acid numbers 24-34 of SEQ ID NO: 4, a CDR2 comprising amino acid numbers 50-56 of SEQ ID NO: 4, and a CDR3 comprising amino acid numbers 89-97 of SEQ ID NO: 4; and

ii) an ErbB3 binding site comprising heavy and light chain variable regions, wherein the heavy chain variable region comprises a CDR1 comprising amino acid numbers 492-501 of SEQ ID NO: 3, a CDR2 comprising amino acid numbers 517-532 of SEQ ID NO: 3, and a CDR3 comprising amino acid numbers 565-577 of SEQ ID NO: 3, and the light chain variable region comprises a CDR1 comprising amino acid numbers 634-644 of SEQ ID NO: 3, a CDR2 comprising amino acid numbers 660-666 of SEQ ID NO: 3, and a CDR3 comprising amino acid numbers 699-709 of SEQ ID NO: 3; and

(b) nab-paclitaxel.

169 . The method of claim 168 , wherein the patient is further administered gemcitabine.

170 . The method of claim 168 , wherein nab-paclitaxel is administered intravenously.

171 . The method of claim 168 , wherein the bispecific binding molecule is administered intravenously at a fixed dose of 2.8 grams every two weeks.

172 . The method of claim 168 , wherein nab-paclitaxel is administered at a dose of 125 mg/m 2 weekly.

173 . The method of claim 169 , wherein gemcitabine is administered at a dose of 1000 mg/m 2 weekly.

174 . The method of claim 169 , wherein nab-paclitaxel and gemcitabine are administered weekly for three weeks and followed by one week of rest.

175 . A method of treating a patient with pancreatic cancer comprising administering to the patient a therapeutically effective amount of:

(a) a bispecific binding molecule comprising:

(i) an IGF-1R binding site comprising heavy and light chain variable regions, wherein the heavy chain variable region comprises amino acids 1-222 of SEQ ID NO: 3 and the light chain variable region comprises amino acids 1-107 of SEQ ID NO: 4, and

(ii) an ErbB3 binding site comprising heavy and light chain variable regions, wherein the heavy chain variable region the comprises amino acids 467-588 of SEQ ID NO: 3 and the light chain variable region comprises amino acids 612-720 of SEQ ID NO: 3; and

(b) nab-paclitaxel.

176 . The method of claim 175 , wherein the bispecific binding molecule comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 3, and a light chain comprising the amino acid sequence of SEQ ID NO: 4.

177 . The method of claim 176 , wherein the bispecific binding molecule is MM-141.

178 . The method of claim 175 , wherein the patient is further administered gemcitabine.

179 . The method of claim 175 , wherein nab-paclitaxel is administered intravenously.

180 . The method of claim 177 , wherein MM-141 is administered intravenously at a fixed dose of 2.8 grams every two weeks.

181 . The method of claim 175 , wherein nab-paclitaxel is administered at a dose of 125 mg/m 2 weekly.

182 . The method of claim 178 , wherein gemcitabine is administered at a dose of 1000 mg/m 2 weekly.

183 . The method of claim 178 , wherein nab-paclitaxel and gemcitabine are administered weekly for three weeks and followed by one week of rest.

184 . A method for treating a patient having pancreatic cancer and identified as having a serum free IGF-1 concentration which is greater than about 15% below a median population level determined in a population having pancreatic cancer, the method comprising administering to the patient a therapeutically effective amount of a bispecific binding molecule comprising:

i) an IGF-1R binding site comprising heavy and light chain variable regions, wherein the heavy chain variable region comprises a CDR1 comprising amino acid numbers 26-35 of SEQ ID NO: 3, a CDR2 comprising amino acid numbers 51-66 of SEQ ID NO: 3, a CDR3 comprising amino acid numbers 99-111 of SEQ ID NO: 3, and the light chain variable region comprises a CDR1 comprising amino acid numbers 24-34 of SEQ ID NO: 4, a CDR2 comprising amino acid numbers 50-56 of SEQ ID NO: 4, and a CDR3 comprising amino acid numbers 89-97 of SEQ ID NO: 4; and

ii) an ErbB3 binding site comprising heavy and light chain variable regions, wherein the heavy chain variable region comprises a CDR1 comprising amino acid numbers 492-501 of SEQ ID NO: 3, a CDR2 comprising amino acid numbers 517-532 of SEQ ID NO: 3, and a CDR3 comprising amino acid numbers 565-577 of SEQ ID NO: 3, and the light chain variable region comprises a CDR1 comprising amino acid numbers 634-644 of SEQ ID NO: 3, a CDR2 comprising amino acid numbers 660-666 of SEQ ID NO: 3, and a CDR3 comprising amino acid numbers 699-709 of SEQ ID NO: 3.

185 . The method of claim 184 , wherein the patient has been identified as having a serum free IGF-1 concentration higher than the median population level.

186 . The method of claim 184 , wherein the patient has been identified as having a serum free IGF-1 concentration greater than about 5% below the median population level.

187 . The method of claim 184 , wherein the patient has been identified as having a serum free IGF-1 concentration greater than about 10% below the median population level.

188 . A method for treating a patient having pancreatic cancer and identified as having a serum free IGF-1 concentration which is greater than about 15% below a median population level determined in a population having pancreatic cancer, the method comprising administering to the patient a therapeutically effective amount of a bispecific binding molecule comprising:

i) an IGF-1R binding site comprising heavy and light chain variable regions, wherein the heavy chain variable region comprises amino acids 1-222 of SEQ ID NO: 3 and the light chain variable region comprises amino acids 1-107 of SEQ ID NO: 4, and

ii) an ErbB3 binding site comprising heavy and light chain variable regions, wherein the heavy chain variable region comprises amino acids 467-588 of SEQ ID NO: 3 and the light chain variable region comprises amino acids 612-720 of SEQ ID NO: 3.

189 . The method of claim 188 , wherein the bispecific binding molecule comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 3, and a light chain comprising the amino acid sequence of SEQ ID NO: 4.

190 . The method of claim 189 , wherein the bispecific binding molecule is MM-141.

191 . The method of claim 188 , wherein the patient has been identified as having a serum free IGF-1 concentration higher than the median population level.

192 . The method of claim 188 , wherein the patient has been identified as having a serum free IGF-1 concentration greater than about 5% below the median population level.

193 . The method of claim 188 , wherein the patient has been identified as having a serum free IGF-1 concentration greater than about 10% below the median population level.

194 . A method of treating a patient with pancreatic cancer comprising administering to the patient MM-141 intravenously at a fixed dose of 2.8 grams every two weeks.

195 . The method of claim 194 , further comprising administering to the patient nab-paclitaxel and gemcitabine as a four-week treatment cycle, wherein the nab-paclitaxel and gemcitabine are administered in each cycle weekly for three weeks followed by one week of rest.

196 . The method of claim 195 , wherein the nab-paclitaxel is administered at a dose of 125 mg/m 2 and the gemcitabine is administered at a dose of 1000 mg/m 2 .